Healthcare’s high-cost, rapidly digitizing profile will persist regardless of how COVID-19 plays out in the coming years. China appears set for consolidation, including in biotech
The market in Asia for genomics related to disease screening will grow 28% between 2020 and 2025 to $11.7 billion, according to McKinsey & Company. During the same period, Asian digital pharmacies will...
Asian private equity has moved on from chasing momentum plays, with GPs increasingly pursuing opportunities where they have domain expertise and know they can add value, the AVCJ Private Equity & Venture Forum heard.
An emerging technology giant has imploded. Regulations are set to tighten. Investors hit pause but remain confident about the long-term outlook. Business as usual in crypto
Patrick Reid, a UK-based managing director for alternatives distribution management at Morgan Stanley, plots the future of themes around secondaries, longer holds, and hybrid approaches to PE
LionRock Capital is exiting Clarks to its majority partner, Li Ning-owned and Hong Kong-listed Viva China, having helped the struggling British shoe brand survive the pandemic